Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
China · Delayed Price · Currency is CNY 55.72
+0.58 (1.05%)
At close: Jun 18, 2026
SHE:301096 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 709.22 | 677.49 | 801.15 | 1,017 | 607.41 | 374.31 |
Other Revenue | 0.49 | 0.49 | 0.77 | 0.11 | - | - |
| 709.72 | 677.99 | 801.92 | 1,017 | 607.41 | 374.31 | |
Revenue Growth (YoY) | -0.73% | -15.46% | -21.18% | 67.51% | 62.27% | 80.61% |
Cost of Revenue | 420.97 | 416.71 | 389.09 | 352.16 | 198.18 | 122.53 |
Gross Profit | 288.74 | 261.28 | 412.83 | 665.28 | 409.23 | 251.78 |
Selling, General & Admin | 126.88 | 125.48 | 92.69 | 139.65 | 104.43 | 57.41 |
Research & Development | 168.63 | 189.5 | 318.03 | 239.64 | 163.03 | 78.33 |
Other Operating Expenses | 13.77 | 4.86 | 9.77 | 5.48 | 10.37 | 0.58 |
Operating Expenses | 334.02 | 343.89 | 458.56 | 404.25 | 286.86 | 140.42 |
Operating Income | -45.27 | -82.6 | -45.73 | 261.04 | 122.37 | 111.36 |
Interest Expense | -22.25 | -21.02 | -16.94 | -7 | -1.32 | -3.67 |
Interest & Investment Income | 1.57 | 2.96 | 13.04 | 28.24 | 42.01 | 2.27 |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.01 | -0 | 1.66 | 1.37 |
Other Non Operating Income (Expenses) | -2.81 | -3.07 | 0.78 | -1.9 | -1.56 | -1.36 |
EBT Excluding Unusual Items | -68.76 | -103.73 | -48.84 | 280.37 | 163.16 | 109.98 |
Gain (Loss) on Sale of Investments | -11.8 | -11.8 | -5.59 | -0.11 | -3.97 | -0.65 |
Gain (Loss) on Sale of Assets | 0.22 | 0.22 | - | 0.78 | 0.02 | - |
Asset Writedown | 0.24 | -0 | -0.01 | -0.03 | -0.03 | -0.07 |
Other Unusual Items | 28.99 | 24.17 | 18.38 | 14.66 | 31.74 | 9.69 |
Pretax Income | -51.11 | -91.14 | -36.06 | 295.68 | 190.91 | 118.95 |
Income Tax Expense | 0.28 | -0.74 | 16.86 | 23.66 | -3.14 | 7.98 |
Earnings From Continuing Operations | -51.39 | -90.4 | -52.92 | 272.01 | 194.04 | 110.97 |
Minority Interest in Earnings | - | - | 0.18 | -0.05 | 0.12 | 0.12 |
Net Income | -51.39 | -90.4 | -52.74 | 271.97 | 194.16 | 111.09 |
Net Income to Common | -51.39 | -90.4 | -52.74 | 271.97 | 194.16 | 111.09 |
Net Income Growth | - | - | - | 40.07% | 74.78% | 93.52% |
Shares Outstanding (Basic) | 109 | 109 | 108 | 108 | 108 | 81 |
Shares Outstanding (Diluted) | 109 | 109 | 108 | 108 | 108 | 81 |
Shares Change (YoY) | 0.83% | 1.18% | -0.66% | -0.11% | 33.77% | 0.29% |
EPS (Basic) | -0.47 | -0.83 | -0.49 | 2.51 | 1.80 | 1.37 |
EPS (Diluted) | -0.47 | -0.83 | -0.49 | 2.51 | 1.79 | 1.37 |
EPS Growth | - | - | - | 40.22% | 30.66% | 92.96% |
Free Cash Flow | -189.88 | -252.56 | -590.96 | -598.15 | -332.16 | -103.02 |
Free Cash Flow Per Share | -1.75 | -2.32 | -5.49 | -5.52 | -3.06 | -1.27 |
Dividend Per Share | - | - | - | 0.300 | 0.800 | 0.600 |
Dividend Growth | - | - | - | -62.50% | 33.33% | - |
Gross Margin | 40.68% | 38.54% | 51.48% | 65.39% | 67.37% | 67.27% |
Operating Margin | -6.38% | -12.18% | -5.70% | 25.66% | 20.15% | 29.75% |
Profit Margin | -7.24% | -13.33% | -6.58% | 26.73% | 31.97% | 29.68% |
Free Cash Flow Margin | -26.75% | -37.25% | -73.69% | -58.79% | -54.68% | -27.52% |
EBITDA | 114.6 | 74.36 | 99.58 | 348.93 | 178.67 | 138.97 |
EBITDA Margin | 16.15% | 10.97% | 12.42% | 34.29% | 29.42% | 37.13% |
D&A For EBITDA | 159.87 | 156.96 | 145.31 | 87.89 | 56.3 | 27.61 |
EBIT | -45.27 | -82.6 | -45.73 | 261.04 | 122.37 | 111.36 |
EBIT Margin | -6.38% | -12.18% | -5.70% | 25.66% | 20.15% | 29.75% |
Effective Tax Rate | - | - | - | 8.00% | - | 6.71% |
Revenue as Reported | 709.72 | 677.99 | 801.92 | 1,017 | 607.41 | 374.31 |
Advertising Expenses | - | 2.49 | 7.34 | 1.72 | 1.38 | 2.75 |